DNAJC12 in Monoamine Metabolism, Neurodevelopment, and Neurodegeneration
暂无分享,去创建一个
M. Farrer | J. Follett | Mengfei Bu | I. Deng | M. Bu | Isaac Bul Deng | Matthew J Farrer | I. Deng | Matthew J. Farrer
[1] Leyli Senturk,et al. A rare cause of hyperphenylalaninemia: four cases from a single family with DNAJC12 deficiency , 2023, Journal of pediatric endocrinology & metabolism : JPEM.
[2] S. Balasubramaniam,et al. Developmental delay and non-phenylketonuria (PKU) hyperphenylalaninemia in DNAJC12 deficiency: Case and approach , 2023, Brain and Development.
[3] F. Porta,et al. Restless legs syndrome in DNAJC12 deficiency , 2023, Neurological Sciences.
[4] Gang Liu,et al. Identification of two novel DNAJC12 gene variants in a patient with mild hyperphenylalaninemia. , 2023, Gene.
[5] P. Gaskill,et al. Dopamine, Immunity, and Disease , 2022, Pharmacological Reviews.
[6] A. Michael-Titus,et al. High phenylalanine concentrations induce demyelination and microglial activation in mouse cerebellar organotypic slices , 2022, Frontiers in Neuroscience.
[7] P. Gaskill,et al. Dopamine and norepinephrine are embracing their immune side and so should we , 2022, Current Opinion in Neurobiology.
[8] J. Ganesh,et al. eP011: Diagnosis of DNAJC12-deficient hyperphenylalaninemia offers targeted therapeutic options to counteract neurotransmitter deficiency , 2022, Genetics in Medicine.
[9] D. Mirowska-Guzel,et al. The Role of Serotonin Neurotransmission in Gastrointestinal Tract and Pharmacotherapy , 2022, Molecules.
[10] M. Ugarte,et al. Diagnosis of inborn errors of metabolism within the expanded newborn screening in the Madrid region , 2022, JIMD reports.
[11] A. Dursun,et al. DNACJ12 deficiency in patients with unexplained hyperphenylalaninemia: two new patients and a novel variant , 2021, Metabolic Brain Disease.
[12] Wei Song,et al. Mutation Analysis of DNAJC Family for Early‐Onset Parkinson's Disease in a Chinese Cohort , 2020, Movement disorders : official journal of the Movement Disorder Society.
[13] Z. Qin,et al. Two novel mutations in DNAJC12 identified by whole‐exome sequencing in a patient with mild hyperphenylalaninemia , 2020, Molecular genetics & genomic medicine.
[14] Aurora Martínez,et al. Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia , 2020, Human mutation.
[15] E. Vidal-Petiot,et al. Adrenergic receptors and cardiovascular effects of catecholamines. , 2020, Annales d'endocrinologie.
[16] Sonja W. Scholz,et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.
[17] C. Blauwendraat,et al. DNAJC proteins and pathways to parkinsonism , 2019, The FEBS journal.
[18] A. Lang,et al. Dystonia and Parkinson's disease: What is the relationship? , 2019, Neurobiology of Disease.
[19] Aurora Martínez,et al. Phenylalanine hydroxylase variants interact with the co‐chaperone DNAJC12 , 2019, Human mutation.
[20] Sichi Liu,et al. Identification of an inherited pathogenic DNAJC12 variant in a patient with hyperphenylalalinemia. , 2019, Clinica chimica acta; international journal of clinical chemistry.
[21] R. G. Correa,et al. Dopamine: Functions, Signaling, and Association with Neurological Diseases , 2018, Cellular and Molecular Neurobiology.
[22] T. Opladen,et al. Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment , 2018, Neuropediatrics.
[23] B. Schweighardt,et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials , 2018, EBioMedicine.
[24] N. Sondheimer,et al. DNAJC12-associated developmental delay, movement disorder, and mild hyperphenylalaninemia identified by whole-exome sequencing re-analysis , 2018, European Journal of Human Genetics.
[25] Changhe Shi,et al. DNAJC12 mutation is rare in Chinese Han population with Parkinson's disease , 2018, Neurobiology of Aging.
[26] Y. Shimo,et al. GCH1 mutations in dopa-responsive dystonia and Parkinson’s disease , 2018, Journal of Neurology.
[27] A. Cuervo,et al. The coming of age of chaperone-mediated autophagy , 2018, Nature Reviews Molecular Cell Biology.
[28] A. Balemans,et al. Beneficial Effect of BH4 Treatment in a 15-Year-Old Boy with Biallelic Mutations in DNAJC12. , 2018, JIMD reports.
[29] M. Cheetham,et al. DNAJ Proteins in neurodegeneration: essential and protective factors , 2018, Philosophical Transactions of the Royal Society B: Biological Sciences.
[30] N. Blau,et al. The complete European guidelines on phenylketonuria: diagnosis and treatment , 2017, Orphanet Journal of Rare Diseases.
[31] V. Sossi,et al. DNAJC12 and dopa‐responsive nonprogressive parkinsonism , 2017, Annals of neurology.
[32] N. Blau,et al. Heterogeneous clinical spectrum of DNAJC12-deficient hyperphenylalaninemia: from attention deficit to severe dystonia and intellectual disability , 2017, Journal of Medical Genetics.
[33] S. Chandra,et al. The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease , 2017, Front. Neurosci..
[34] N. Spencer,et al. The Diverse Metabolic Roles of Peripheral Serotonin. , 2017, Endocrinology.
[35] Edward L. Huttlin,et al. Biallelic Mutations in DNAJC12 Cause Hyperphenylalaninemia, Dystonia, and Intellectual Disability. , 2017, American journal of human genetics.
[36] M. Zigmond,et al. The Molecular Chaperone Hsc70 Interacts with Tyrosine Hydroxylase to Regulate Enzyme Activity and Synaptic Vesicle Localization* , 2016, The Journal of Biological Chemistry.
[37] L. Arendt-Nielsen,et al. Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives , 2016, Behavioural neurology.
[38] K. Channon,et al. Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway , 2015, Neuron.
[39] M. Farrer,et al. Parkinsonism in GTP cyclohydrolase 1 mutation carriers. , 2015, Brain : a journal of neurology.
[40] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[41] J. Homberg,et al. The neurodevelopmental effects of serotonin: A behavioural perspective , 2015, Behavioural Brain Research.
[42] T. Dinan,et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis , 2015, Behavioural Brain Research.
[43] J. Vockley,et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial , 2014, The Lancet.
[44] A. Singleton,et al. Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers , 2014, Brain : a journal of neurology.
[45] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[46] C. Labrie,et al. The co-chaperone DNAJC12 binds to Hsc70 and is upregulated by endoplasmic reticulum stress , 2014, Cell stress & chaperones (Print).
[47] Wyeth W Wasserman,et al. DNAJC13 mutations in Parkinson disease. , 2014, Human molecular genetics.
[48] Amanda J. Moffitt,et al. The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria☆ , 2013, NeuroImage: Clinical.
[49] J. A. van Hooft,et al. The serotonin 5-HT3 receptor: a novel neurodevelopmental target , 2013, Front. Cell. Neurosci..
[50] D. Aarsland,et al. Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management , 2013, Drugs & Aging.
[51] N. Blau,et al. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia , 2012, Journal of Inherited Metabolic Disease.
[52] K. Kaestner,et al. A Deleterious Mutation in DNAJC6 Encoding the Neuronal-Specific Clathrin-Uncoating Co-Chaperone Auxilin, Is Associated with Juvenile Parkinsonism , 2012, PloS one.
[53] P. McHugh. The tetrahydrobiopterin pathway: a novel target for the treatment of depression. , 2011, Pharmacogenomics.
[54] E. Werner,et al. Tetrahydrobiopterin: biochemistry and pathophysiology. , 2011, The Biochemical journal.
[55] C. van Broeckhoven,et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. , 2011, American journal of human genetics.
[56] John J. Mitchell,et al. Phenylalanine hydroxylase deficiency , 2011, Genetics in Medicine.
[57] C. Klein,et al. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia , 2011, Movement disorders : official journal of the Movement Disorder Society.
[58] Elizabeth A. Daubert,et al. Serotonin: a regulator of neuronal morphology and circuitry , 2010, Trends in Neurosciences.
[59] D. Zafeiriou,et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. , 2010, Brain : a journal of neurology.
[60] Raphaël Marée,et al. Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites , 2010, Journal of Inherited Metabolic Disease.
[61] V. Faundez,et al. A Biochemical and Functional Protein Complex Involving Dopamine Synthesis and Transport into Synaptic Vesicles , 2009, The Journal of Biological Chemistry.
[62] M. Farrer,et al. GCH1 in early‐onset Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[63] R. Wise. Roles for nigrostriatal—not just mesocorticolimbic—dopamine in reward and addiction , 2009, Trends in Neurosciences.
[64] R. Leak,et al. The molecular chaperone Hsc70 interacts with the vesicular monoamine transporter‐2 , 2009, Journal of neurochemistry.
[65] A. Arnsten. Stress signalling pathways that impair prefrontal cortex structure and function , 2009, Nature Reviews Neuroscience.
[66] Hsiu-Fen Lee,et al. Aromatic L-amino acid decarboxylase deficiency in Taiwan. , 2009, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[67] M. Fernstrom,et al. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. , 2007, The Journal of nutrition.
[68] Jörn Lötsch,et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence , 2006, Nature Medicine.
[69] R. Artuch,et al. Cognitive functions in classic phenylketonuria and mild hyperphenyl‐alaninaemia: experience in a paediatric population , 2005 .
[70] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[71] D. Chugani. Role of altered brain serotonin mechanisms in autism , 2002, Molecular Psychiatry.
[72] Kae Nakamura,et al. Central mechanisms of motor skill learning , 2002, Current Opinion in Neurobiology.
[73] P. Huttenlocher. The neuropathology of phenylketonuria: human and animal studies , 2000, European Journal of Pediatrics.
[74] E. Daikhin,et al. Is there a relationship between 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse? , 2000, Journal of neuroscience research.
[75] A. Cuervo,et al. A Receptor for the Selective Uptake and Degradation of Proteins by Lysosomes , 1996, Science.
[76] A. Kendler,et al. Evidence for Central Nervous System Glial Cell Plasticity in Phenylketonuria , 1996, Journal of neuropathology and experimental neurology.
[77] Aurora Martínez,et al. DNAJC12 deficiency: A new strategy in the diagnosis of hyperphenylalaninemias. , 2018, Molecular genetics and metabolism.
[78] C. Harding,et al. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU). , 2016, Molecular genetics and metabolism.
[79] A William Tank,et al. Peripheral and central effects of circulating catecholamines. , 2015, Comprehensive Physiology.
[80] R. Kvetňanský,et al. Stress-triggered changes in peripheral catecholaminergic systems. , 2013, Advances in pharmacology.
[81] C. Ficicioglu,et al. Dihydropteridine reductase deficiency and treatment with tetrahydrobiopterin: a case report. , 2013, JIMD reports.
[82] C. Dyer. Pathophysiology of phenylketonuria , 1999 .
[83] Robert S. Lockhart,et al. Learning and Motivation , 1981 .